Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe.
Ran JinChidozie U NdukaDelphine CourmierHannah KnightRachael MeadowsJames PiercyJ R Fraser CummingsWaldemar RadziszewskiPublished in: Advances in therapy (2023)
Both patients with IBD and treating physicians reported high levels of satisfaction with ABP 501 among initiators and switchers.